A First for UK Pharma: CNX Therapeutics Exceeds Global B Corp Standard
London, Tuesday 18 March 2025 – CNX Therapeutics Limited (“CNX Therapeutics” / “CNX”), has become the first UK-based pharmaceutical company to exceed B Corporation (B Corp) standards. This achievement makes CNX part of an international community of companies recognised for their positive social and environmental impact through B Corp certification.
The successful completion of this rigorous process marks a significant milestone in CNX’s commitment to maintaining high-quality social and environmental standards.
With an overall B Impact Score of 103.2, CNX Therapeutics has far exceeded the 80-point threshold required for B Corp certification. This outstanding score positions the company as one of the leading purpose-driven businesses, well above the average score of 50.9 for ordinary companies attempting to achieve certification.
Sarah Morbey, Vice President, Legal and ESG at CNX Therapeutics, said: “Achieving B-Corp certification on our first attempt is a phenomenal achievement and a reflection of our collective commitment to sustainability. From reducing emissions to supporting communities, every step we take is guided by our mission to make a positive impact. This milestone celebrates our progress and inspires us to do even more as we look ahead to recertification in three years.”
Guy Clark, CEO of CNX Therapeutics, added: “Becoming the first UK pharma company to achieve B-Corp certification reflects our team’s passion and belief in using business as a force for good. We’ve shown that purpose and profit can go hand in hand, and this is just the start. We’ll continue to innovate and lead by example, creating a better future for our people, planet and patients.”
CNX Therapeutics’ B-Corp certification reflects its comprehensive sustainability efforts. The company supports the Women’s Empowerment Principles, aligns with SDG5 on Gender Equality, and participates in the UN Global Compact, demonstrating its commitment to human rights, labour, environmental sustainability, and anti-corruption.
Additionally, CNX provides essential medicines on the WHO Essential Medicines List and partners with Evertreen on a reforestation project in British Columbia, which has planted hundreds of trees and offset over 10,000 tons of CO₂.
Chris Turner, Executive Director of B Lab UK, said: “Welcoming CNX Therapeutics to the B Corp community is hugely exciting. Its commitment to doing business differently will be an inspiration to others and will help spread the notion that success in business is as much about people and planet as it is profit.”
Since its acquisition by Inflexion Private Equity in 2021, CNX has secured B Corp certification, making it one of five companies in Inflexion’s portfolio to achieve this recognition and reinforcing its position as an ESG leader.
